Cargando…

Treatment Status and Healthcare Cost Trends for Patients with Multiple Sclerosis in Japan: A Claims Database Analysis

INTRODUCTION: The healthcare situation of multiple sclerosis (MS) and its course are not being thoroughly investigated in Japan. We aimed to examine the current healthcare situation, including treatment and healthcare costs, of MS according to duration since its first diagnosis using Japanese real-w...

Descripción completa

Detalles Bibliográficos
Autores principales: Kawachi, Izumi, Otaka, Hiromichi, Iwasaki, Kosuke, Takeshima, Tomomi, Ueda, Kengo
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Healthcare 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9338194/
https://www.ncbi.nlm.nih.gov/pubmed/35713761
http://dx.doi.org/10.1007/s40120-022-00374-4
_version_ 1784759915417436160
author Kawachi, Izumi
Otaka, Hiromichi
Iwasaki, Kosuke
Takeshima, Tomomi
Ueda, Kengo
author_facet Kawachi, Izumi
Otaka, Hiromichi
Iwasaki, Kosuke
Takeshima, Tomomi
Ueda, Kengo
author_sort Kawachi, Izumi
collection PubMed
description INTRODUCTION: The healthcare situation of multiple sclerosis (MS) and its course are not being thoroughly investigated in Japan. We aimed to examine the current healthcare situation, including treatment and healthcare costs, of MS according to duration since its first diagnosis using Japanese real-world data to determine unidentified healthcare issues at each disease stage. METHODS: This retrospective, non-comparative, non-interventional study used a Japanese nationwide claims database (April 2008–August 2018) comprising 20 million patients from 329 acute care hospitals (as of June 2018). Treatment patterns, comorbidities, healthcare resource utilization, and healthcare costs were analyzed using longitudinal analyses of patients with MS according to duration since the first diagnosis. The time from diagnosis to first treatment was examined using Kaplan–Meier analysis. RESULTS: We identified 7067 patients with MS [mean (standard deviation) age at first diagnosis 45.0 (16.2) years]. About 70% of the patients did not receive disease-modifying therapy (DMT) within the first year of diagnosis. The frequency of DMT use decreased in patients with a longer duration since the first diagnosis. MS treatment costs tended to increase with a longer duration from the first diagnosis until 9 years, followed by a tendency to decrease; contrastingly, other healthcare costs tended to increase with duration after decreasing from the year of the first diagnosis to the next year. The frequencies of hospitalizations and hospital visits, healthcare costs—excluding those for MS treatment and tests—and prevalence of comorbidities tended to be higher in patients with a longer duration since the first diagnosis. CONCLUSION: A considerable proportion of patients did not receive DMT, suggesting that patients with early-stage MS may lose the opportunity to improve their prognosis through early intervention with DMT. Among patients with a longer duration since the first diagnosis, fewer treatment choices may be available despite the larger clinical and treatment burden. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1007/s40120-022-00374-4.
format Online
Article
Text
id pubmed-9338194
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Springer Healthcare
record_format MEDLINE/PubMed
spelling pubmed-93381942022-07-31 Treatment Status and Healthcare Cost Trends for Patients with Multiple Sclerosis in Japan: A Claims Database Analysis Kawachi, Izumi Otaka, Hiromichi Iwasaki, Kosuke Takeshima, Tomomi Ueda, Kengo Neurol Ther Original Research INTRODUCTION: The healthcare situation of multiple sclerosis (MS) and its course are not being thoroughly investigated in Japan. We aimed to examine the current healthcare situation, including treatment and healthcare costs, of MS according to duration since its first diagnosis using Japanese real-world data to determine unidentified healthcare issues at each disease stage. METHODS: This retrospective, non-comparative, non-interventional study used a Japanese nationwide claims database (April 2008–August 2018) comprising 20 million patients from 329 acute care hospitals (as of June 2018). Treatment patterns, comorbidities, healthcare resource utilization, and healthcare costs were analyzed using longitudinal analyses of patients with MS according to duration since the first diagnosis. The time from diagnosis to first treatment was examined using Kaplan–Meier analysis. RESULTS: We identified 7067 patients with MS [mean (standard deviation) age at first diagnosis 45.0 (16.2) years]. About 70% of the patients did not receive disease-modifying therapy (DMT) within the first year of diagnosis. The frequency of DMT use decreased in patients with a longer duration since the first diagnosis. MS treatment costs tended to increase with a longer duration from the first diagnosis until 9 years, followed by a tendency to decrease; contrastingly, other healthcare costs tended to increase with duration after decreasing from the year of the first diagnosis to the next year. The frequencies of hospitalizations and hospital visits, healthcare costs—excluding those for MS treatment and tests—and prevalence of comorbidities tended to be higher in patients with a longer duration since the first diagnosis. CONCLUSION: A considerable proportion of patients did not receive DMT, suggesting that patients with early-stage MS may lose the opportunity to improve their prognosis through early intervention with DMT. Among patients with a longer duration since the first diagnosis, fewer treatment choices may be available despite the larger clinical and treatment burden. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1007/s40120-022-00374-4. Springer Healthcare 2022-06-17 /pmc/articles/PMC9338194/ /pubmed/35713761 http://dx.doi.org/10.1007/s40120-022-00374-4 Text en © The Author(s) 2022 https://creativecommons.org/licenses/by-nc/4.0/Open AccessThis article is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License, which permits any non-commercial use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by-nc/4.0/ (https://creativecommons.org/licenses/by-nc/4.0/) .
spellingShingle Original Research
Kawachi, Izumi
Otaka, Hiromichi
Iwasaki, Kosuke
Takeshima, Tomomi
Ueda, Kengo
Treatment Status and Healthcare Cost Trends for Patients with Multiple Sclerosis in Japan: A Claims Database Analysis
title Treatment Status and Healthcare Cost Trends for Patients with Multiple Sclerosis in Japan: A Claims Database Analysis
title_full Treatment Status and Healthcare Cost Trends for Patients with Multiple Sclerosis in Japan: A Claims Database Analysis
title_fullStr Treatment Status and Healthcare Cost Trends for Patients with Multiple Sclerosis in Japan: A Claims Database Analysis
title_full_unstemmed Treatment Status and Healthcare Cost Trends for Patients with Multiple Sclerosis in Japan: A Claims Database Analysis
title_short Treatment Status and Healthcare Cost Trends for Patients with Multiple Sclerosis in Japan: A Claims Database Analysis
title_sort treatment status and healthcare cost trends for patients with multiple sclerosis in japan: a claims database analysis
topic Original Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9338194/
https://www.ncbi.nlm.nih.gov/pubmed/35713761
http://dx.doi.org/10.1007/s40120-022-00374-4
work_keys_str_mv AT kawachiizumi treatmentstatusandhealthcarecosttrendsforpatientswithmultiplesclerosisinjapanaclaimsdatabaseanalysis
AT otakahiromichi treatmentstatusandhealthcarecosttrendsforpatientswithmultiplesclerosisinjapanaclaimsdatabaseanalysis
AT iwasakikosuke treatmentstatusandhealthcarecosttrendsforpatientswithmultiplesclerosisinjapanaclaimsdatabaseanalysis
AT takeshimatomomi treatmentstatusandhealthcarecosttrendsforpatientswithmultiplesclerosisinjapanaclaimsdatabaseanalysis
AT uedakengo treatmentstatusandhealthcarecosttrendsforpatientswithmultiplesclerosisinjapanaclaimsdatabaseanalysis